SCHEMBL1879428

SCHEMBL1879428

Nc1nc(-c2cccc(OCc3ccc(OC(F)(F)F)cc3)c2)c2cc(Cl)ccc2n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.48
HSP90AB1 P08238 1/20 0.44
SLC9A3 P48764 1/20 0.44
ADORA2A P29274 2/20 0.43
DHODH Q02127 1/20 0.42
DHFR P00374 3/20 0.42
IGF1R P08069 2/20 0.40
DCPS Q96C86 1/20 0.40
MAPT P10636 2/20 0.39
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.39
HPGD P15428 1/20 0.39
KMT2A Q03164 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
SLC6A4 P31645 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
PTGS1 P23219 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1879142 0.92 BACE1 (0.48) BACE1HSP90AB1SLC9A3ADORA2ADHODH
SCHEMBL1879985 0.90 BACE1 (0.55) BACE1HSP90AB1SLC9A3ADORA2ADHFR
SCHEMBL1879206 0.89 BACE1 (0.49) BACE1HSP90AB1SLC9A3ADORA2ADHFR
SCHEMBL1877697 0.88 BACE1 (0.52) BACE1HSP90AB1SLC9A3ADORA2ADHFR
SCHEMBL1876600 0.86 HSP90AB1 (0.62) BACE1HSP90AB1SLC9A3ADORA2ADHFR
SCHEMBL1881986 0.85 DHFR (0.55) BACE1HSP90AB1SLC9A3ADORA2ADHFR
SCHEMBL1875717 0.85 NR1H2 (0.49) BACE1HSP90AB1SLC9A3ADORA2ADHFR
SCHEMBL1877258 0.84 BACE1 (0.52) BACE1HSP90AB1SLC9A3ADORA2ADHFR
SCHEMBL1877640 0.83 BACE1 (0.49) BACE1HSP90AB1SLC9A3ADORA2ADHFR
SCHEMBL1883379 0.83 RXRA (0.58) BACE1HSP90AB1SLC9A3MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7947696-B2 heat shock proteins inhibition, regulation and/or modulation; tumour diseases, viral diseases, for immune suppression in transplants, inflammation-induced diseases, cystic fibrosis, diseases associated with angiogenesis, infectious diseases, autoimmune diseases, ischaemia, fibrogenetic diseases MERCK PATENT GMBH (DE) 2011-05-24 US claimed
US-20080214586-A1 2-Amino-4-Phenylquinazoline Derivatives and the Use Thereof as Hsp90 Modulators MERCK PATENT GMBH (DE) 2008-09-04 US claimed
CN-101180278-A 2-amino-4-phenylquinazoline derivates and their use as HSP90 modulators MERCK PATENT GMBH (DE) 2008-05-14 CN claimed
US-7947696-B2 heat shock proteins inhibition, regulation and/or modulation; tumour diseases, viral diseases, for immune suppression in transplants, inflammation-induced diseases, cystic fibrosis, diseases associated with angiogenesis, infectious diseases, autoimmune diseases, ischaemia, fibrogenetic diseases MERCK PATENT GMBH (DE) 2011-05-24 US disclosed
CN-101180278-B 2-amino-4-phenylquinazoline derivates and their use as HSP90 modulators MERCK PATENT GMBH 2011-05-04 CN disclosed
US-20080214586-A1 2-Amino-4-Phenylquinazoline Derivatives and the Use Thereof as Hsp90 Modulators MERCK PATENT GMBH (DE) 2008-09-04 US disclosed
CN-101180278-A 2-amino-4-phenylquinazoline derivates and their use as HSP90 modulators MERCK PATENT GMBH (DE) 2008-05-14 CN disclosed
EP-1881965-A1 2-AMINO-4-PHENYLQUINAZOLINE DERIVATES AND THEIR USE AS HSP90 MODULATORS Merck Patent GmbH (DE) 2008-01-30 EP disclosed
WO-2006122631-A1 2-AMINO-4-PHENYLQUINAZOLINE DERIVATES AND THEIR USE AS HSP90 MODULATORS MERCK PATENT GMBH (DE) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214586-A1 2-Amino-4-Phenylquinazoline Derivatives and the Use Thereof as Hsp90 Modulators HSP90AB2P, HSP90AB1, HSP90AA1 BACE1 4518/4885HSP90AB1 2/4885SLC9A3 2685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.